Atlanta, GANCT06936566Now EnrollingIRB Ready

Graft-versus-host Disease Clinical Trial in Atlanta, GA

Access cutting-edge graft-versus-host disease treatment through this phase 2 clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by John Levine

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access graft-versus-host disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related graft-versus-host disease treatment provided free

Apply for This Atlanta Location

Check if you qualify for this graft-versus-host disease clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Graft-versus-host Disease Study in Atlanta

This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The most common symptoms are skin rash, jaundice, nausea, vomiting, and/or diarrhea. The standard treatment for GVHD is high dose steroids such as prednisone or methylprednisolone, which suppresses the donor cells, but sometimes there can be either no respon

Sponsor: John Levine

Who Can Participate

Inclusion Criteria

Standard risk cohort: Minnesota standard risk GVHD (except patients with grade I \[\<50% BSA rash\])
High risk cohort: Minnesota high risk GVHD 3 GVHD that developed after DLI for mixed chimerism or poor graft function is allowed
No prior systemic acute GVHD treatment. Topical or non-absorbed steroids are permitted.
All donor types, HLA-matches, conditioning regimens, or GVHD prophylaxis strategies are acceptable
≥18 years of age
Standard risk cohort: Hematopoietic engraftment with absolute neutrophil count (ANC) ≥ 1000/μL and platelet count ≥20,000. Use of growth factor supplementation and transfusions to maintain adequate hematologic parameters are allowed.
High risk cohort: Hematopoietic engraftment with ANC ≥ 500/uL and platelet count ≥20,000. Use of growth factor supplementation and transfusions to maintain adequate hematologic parameters are allowed.

Exclusion Criteria

Systemic treatment with ruxolitinib or any other JAK inhibitor within 7 days of study entry
Prior use of ruxolitinib to treat GVHD at any time
Relapsed, progressing or persistent malignancy requiring withdrawal of systemic immunosuppression
Relapse prior to development of GVHD unless subsequently in remission for at least 3 months
GVHD that developed after DLI for relapse is not allowed without study PI or medical monitor approval
Uncontrolled infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis)
Severe organ dysfunction within 3 days of enrollment including requirement for dialysis, mechanical ventilation, continuous BiPAP, or continuous high flow oxygen by nasal cannula, or total bilirubin ≥ 3x upper limit of normal not due to GVHD.
A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment (except for mild oral or ocular GVHD)
Corticosteroids \>10 mg/day methylprednisolone (or other methylprednisolone equivalent, MPE) for any indication within 5 days before the onset of acute GVHD except for adrenal insufficiency or premedication for transfusions/IV meds
Participation in clinical trials using experimental agents not approved by the FDA for any indication within 14 days of enrollment or five half-lives, whichever is longer provided any prior adverse events have improved to ≤grade 1
Patients who are pregnant or nursing
History of allergic reaction to ruxolitinib or any JAK inhibitor

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT06936566) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Graft-versus-host Disease Treatment Options in Atlanta, GA

If you're searching for graft-versus-host disease treatment options in Atlanta, GA, this clinical trial (NCT06936566) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all graft-versus-host disease clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Atlanta, GA

See all atrial fibrillation clinical trials recruiting in Atlanta — not just this study.

Browse Atrial Fibrillation Trials in Atlanta →

Browse More Trials by Condition

Atrial Fibrillation TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA